~~<i id='31AF468BEA'><strike id='31AF468BEA'><tt id='31AF468BEA'><pre id='31AF468BEA'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：entertainment 2025-09-28 15:07:23 Page View：7

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Covid vaccine financial winners and losers, from Pfizer to Novavax
Next article： Psychedelics group wrestles with new pharma identity

explore

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Wegovy’s successful heart trial raises vital question about weight loss

BloombergAlandmarkstudythatfoundtheblockbusterobesitydrugWegovyreducesthechanceofheartproblemsaddsur

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Donor acceptance rates hint at racial, gender bias in heart transplants: study

AdobeWhenapatientisgoingthroughend-stageheartfailure,thebesttreatmentistogetahearttransplant.Thebasi